PhaseBio Pharmaceuticals

General Information


We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. Our lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor, which we are developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. We recently completed a Phase 1 clinical trial of PB2452 in healthy subjects. Our second product candidate, PB1046, is a once-weekly fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension, or PAH. PB1046 utilizes our proprietary half-life extending elastin-like polypeptide, or ELP, technology, which also serves as the engine for our preclinical pipeline. We retain worldwide rights to all of our product candidates.

Employees: 19
Founded: 2002
Contact Information
Address 1 Great Valley Parkway, Suite 30, Malvern, PA 19355, US
Phone Number (610) 981-6500
Web Address
View Prospectus: PhaseBio Pharmaceuticals
Financial Information
Market Cap $254.6mil
Revenues $0 mil (last 12 months)
Net Income $-16.2 mil (last 12 months)
IPO Profile
Symbol PHAS
Exchange NASDAQ
Shares (millions): 9.2
Price range $5.00 - $5.00
Est. $ Volume $46.0 mil
Manager / Joint Managers Citigroup/ Cowen/ Stifel
CO-Managers Needham
Expected To Trade: 10/18/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change